Investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in SSA and Europe

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$499,605.12
Funder
European & Developing Countries Clinical Trials Partnership (EDCTP)
Principal Investigator
Pending
Research Location
Uganda, South Africa
Lead Research Institution
N/A
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Subject
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

The COVAB project (RIA2020EF-3008) aims to understand antibody evolution following exposure to and/or SARS-CoV-2 infection, and to investigate factors associated with infection by SARS-CoV-2 across oral and nasal mucosa biopsies.

Publicationslinked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.

Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.

The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.

An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2.

The Distinct Absence of a Post-boost Spike-IgG Antibody Surge in Ugandan Recipients of the Pfizer-BioNTech Vaccine Has Implications for Vaccination Policies

Evaluation of a human mucosal tissue explant model for SARS-CoV-2 replication.

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection.

Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.